Saturday 17 October 2026
Export SERA’s income statement to Excel — free account
Sera Prognostics, Inc.
SERA Healthcare Medical Devices
Sera Prognostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $81,000.00, up 5.19% from fiscal 2024. In the quarter to June 2026, revenue grew 76.5%, EPS fell 12.5% and free cash flow fell 10.6%, each against the same quarter a year earlier.
2.06
0.03
+1.48%
Follow SERA
Sera Prognostics, Inc. (SERA) P/E ratio
Sera Prognostics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 20 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| HYPR Hyperfine, Inc. compare | n/m |
| ECOR electroCore, Inc. compare | n/m |
| SERA Sera Prognostics, Inc. | n/m |
| LUCD Lucid Diagnostics Inc. compare | n/m |
| ZOMDF Zomedica Corp. compare | n/m |
| LUNG Pulmonx Corporation compare | n/m |
| OM Outset Medical, Inc. compare | n/m |
| APYX Apyx Medical Corporation compare | n/m |
| LNSR LENSAR, Inc. compare | 2.0× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)